RESUMO
PURPOSE: We prospectively evaluated a new treatment for recalcitrant choroidal neovascularization (CNV) in 4 patients. We used an infrared laser (810 nm) in oscillatory thermotherapy (OTT) mode combined with indocyanine green (ICG) dye, utilizing the beneficial effect of both thermotherapy and photodynamic therapy. We describe preliminary experiences with ICG-assisted OTT (I-OTT) combined with intravitreal bevacizumab/dexamethasone for refractory peripapillary CNV resistant to standard therapy. METHODS: Clinical examination, funduscopy, fluorescein angiography, and optical coherence tomography were performed at baseline and postoperatively. Infrared laser spot size was approximately one-half the lesion size (oscillation 2-3 Hz). Intravitreal injections of bevacizumab (1.25 mg) and dexamethasone (1000 µg) were done during the same visit. RESULTS: Mean follow-up was 12.5 months (range 5-17). Mean energy level was 325 mW (range 200-500) in oscillatory mode (2-3 Hz/sec) pre- and post-ICG infusion. Indocyanine green dose was approximately 1 mg/kg (75 mg/patient). All patients had a single treatment. Mean visual acuity improved in 1 patient from 20/60 to 20/30 and remained the same in the other 3 (20/20, 20/40, and 20/400). At final examination, there was no evidence of clinical or angiographic activity of CNV. CONCLUSIONS: Indocyanine green-assisted OTT has the potential to treat CNV in wet age-related macular degeneration. It may reduce thermal side effects and eliminate or reduce the need for frequent intravitreal treatment. We postulate that I-OTT has a synergistic effect of thermal energy combined with a weak photosensitizer (ICG) applied in an individualized manner, which minimizes thermal damage to retinal and choroidal tissue. Additional anti-vascular endothelial growth factor pharmacotherapy enhances the effect of I-OTT on abnormal new vessels.
Assuntos
Inibidores da Angiogênese/uso terapêutico , Anticorpos Monoclonais/uso terapêutico , Neovascularização de Coroide/terapia , Dexametasona/uso terapêutico , Glucocorticoides/uso terapêutico , Hipertermia Induzida , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Idoso de 80 Anos ou mais , Anticorpos Monoclonais Humanizados , Bevacizumab , Corantes , Terapia Combinada , Quimioterapia Combinada , Feminino , Angiofluoresceinografia , Seguimentos , Humanos , Verde de Indocianina , Masculino , Pessoa de Meia-Idade , Oftalmoscopia , Disco Óptico , Estudos Prospectivos , Pupila , Tomografia de Coerência ÓpticaRESUMO
Age-related macular degeneration is a chronic disease leading to progressive central vision loss. It is the leading cause of irreversible blindness in the United States, most commonly affecting white Caucasians aged more than 55 years. Typical symptoms include decreased central vision, central scotoma, and metamorphopsia. Patients with acute loss of vision should be promptly referred to an ophthalmologist. New antiangiogenic therapies have significantly improved visual prognosis in these patients.